Multiple BCL2 mutations cooccurring with Gly101Val emerge in chronic lymphocytic leukemia progression on venetoclax
Top Cited Papers
Open Access
- 5 March 2020
- journal article
- research article
- Published by American Society of Hematology in Blood
- Vol. 135 (10), 773-+
- https://doi.org/10.1182/blood.2019004205
Abstract
The BCL2 inhibitor venetoclax has complete response rates of up to 50% in chronic lymphocytic leukemia patients, but secondary resistance reflecting acquired muThis publication has 28 references indexed in Scilit:
- Faculty Opinions recommendation of Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study.Published by H1 Connect ,2017
- Detection of clinically relevant early genomic lesions in B‐cell malignancies from circulating tumour DNA using a single hybridisation‐based next generation sequencing assayBritish Journal of Haematology, 2017
- Clinicopathological features and outcomes of progression of CLL on the BCL2 inhibitor venetoclaxBlood, 2017
- Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patientsNature Medicine, 2017
- Mutations of CREBBP and SOCS1 are independent prognostic factors in diffuse large B cell lymphoma: mutational analysis of the SAKK 38/07 prospective clinical trial cohortJournal of Hematology & Oncology, 2017
- Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b studyThe Lancet Oncology, 2017
- Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 studyThe Lancet Oncology, 2016
- Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic LeukemiaThe New England Journal of Medicine, 2016
- ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing plateletsNature Medicine, 2013
- ABT-263: A Potent and Orally Bioavailable Bcl-2 Family InhibitorCancer Research, 2008